NitroMed (NTMD) Reports a Q3 Loss of $0.45
More News related to NTMD
- NitroMed (NTMD) Announces Merger Agreement with Deerfield Management
- NitroMed (NTMD) Agrees to be Acquired by Deerfield Management for $0.80/Share
- Deerfield Management Increases Its Offer For NitroMed (NTMD)
- NitroMed (NTMD) Confirms Receipt of Letter from Deerfield Management
- Notable Mergers and Acquisitions of the Day 12/05: MER/BAC, NTMD, RSG/AW
More News related to Earnings
- Communications Systems (JCS) Reports Year-Over-Year Decline in Q3 Earnings
- Communications Systems (JCS) Posts Q3 EPS of $0.22, Down Y/Y
- Atmos Energy (ATO) Posts Q4 Loss of $0.17, Wider than Estimates
- China Digital TV (STV) Misses Q3 EPS by 2c; Guides Below for Q4
- Ralcorp (RAH) Misses Street's Q4 Views; Announces 7M Share Buyback
NitroMed Inc. (Nasdaq: NTMD) reports a Q3 loss of $0.45, in-line with estimates. Revenues were $3.43 million vs. $3.63 million consensus.
NitroMed of Lexington, Massachusetts is an emerging pharmaceutical company and the maker of BiDil® (isosorbide dinitrate/hydralazine hydrochloride), an orally administered medicine available in the United States for the treatment of heart failure in self-identified black patients.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
